Cargando…
Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
Acute exacerbations of COPD (AECOPD) are major clinical events. They are associated with a more rapid decline in lung function, poorer quality of life scores, and an increased risk of dying. Exacerbations that require hospitalization have particular significance. Approximately 40% of the AECOPD pati...
Autor principal: | Field, Stephen K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212861/ https://www.ncbi.nlm.nih.gov/pubmed/22084617 http://dx.doi.org/10.4137/CCRPM.S7049 |
Ejemplares similares
-
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010) -
Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012) -
Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015) -
Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
por: Rennard, Stephen I, et al.
Publicado: (2011) -
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007)